HC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. B. Riley lowered their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Stock Down 0.8 %

PDS Biotechnology stock opened at $1.26 on Monday. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12-month low of $1.20 and a 12-month high of $6.68. The firm’s fifty day moving average is $1.55 and its 200 day moving average is $2.45. The company has a market capitalization of $47.14 million, a PE ratio of -1.09 and a beta of 1.88.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after purchasing an additional 37,142 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after purchasing an additional 76,800 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after purchasing an additional 48,132 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.